Overview

Bioequivalence Study of Moksi® 400mg Tablet and Avelox® 400mg Tablet (Moxifloxacin) Under Fasting Condition in Healthy Adult Pakistani Subjects

Status:
Completed
Trial end date:
2019-04-27
Target enrollment:
Participant gender:
Summary
Single dose, two way crossover Bioequivalence (BE) study to evaluate the comparative bioavailability of moxifloxacin.
Phase:
Phase 1
Details
Lead Sponsor:
Abbott
Treatments:
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination